Back to search results

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

This study is looking for people aged 18 or older who have recently had an allogeneic stem cell transplant (alloSCT) between 90 and 180 days ago. The purpose is to collect information about chronic graft-versus-host disease (cGVHD), a condition that can happen after a stem cell transplant. This is an observational study, meaning you won't receive any new treatments; instead, researchers will gather data about your health over 36 months. The main goal is to understand the overall impact and severity of cGVHD. The study is currently recruiting participants.

Study design
This is an observational study that plans to enroll 1500 participants. It is not testing a specific treatment.
What's involved
You would complete participant-assessment questionnaires, either on your own or with some help.
Compensation
Not stated in the trial record.
Follow-up
Your health will be observed for 36 months to measure the burden of cGVHD.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05919511

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Recruiting
Not specifiedAges 18+Observational
Incyte Corporation
~1,500 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Non-Interventional

At a glance

Recruiting sites
31 of 32 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Burden of cGVHD diagnosis and severity
Measured over 36 months

Conditions

cGVHD

Explore related trials

Chronic Graft Versus Host Disease

NCT05919511

Where you'd take part

This study runs at 32 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AdventHealth Orlando

    Orlando, Floridano site contact published

    Recruiting

  • City of Hope

    Duarte, Californiano site contact published

    Recruiting

  • Corewell Health

    Grand Rapids, Michiganno site contact published

    Recruiting

  • Emory University

    Atlanta, Georgiano site contact published

    Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washingtonno site contact published

    Recruiting

  • Geisinger Health Systems

    Danville, Pennsylvaniano site contact published

    Recruiting

  • Georgia Cancer Center

    Augusta, Georgiano site contact published

    Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolinano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years inclusive at the time of signing the ICF
Allogeneic SCT 90 to 180 days prior to enrollment
Able to comprehend and willing to provide informed consent
Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel

What this trial measures

  • Overall Burden of cGVHD diagnosis and severity36 months